Neurocognitive Characteristics of Patients Who Visited a Psychiatric Outpatient Clinic Requesting Treatment for Adult Attention-Deficit/Hyperactivity Disorder

Article information

Psychiatry Investig. 2024;21(9):958-970
Publication date (electronic) : 2024 August 20
doi : https://doi.org/10.30773/pi.2024.0066
1Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea
2Department of Human Systems Medicine, Seoul National University, Seoul, Republic of Korea
3Department of Psychiatry, National Traffic Injury Rehabilitation Hospital, Yangpyeong, Republic of Korea
4Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea
5Clinical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea
Correspondence: Ung Gu Kang, MD, PhD Department of Psychiatry, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea Tel: +82-2-2072-2450, Fax: +82-2-765-7431, E-mail: kangug@snu.ac.kr
Received 2024 February 25; Revised 2024 May 10; Accepted 2024 June 1.

Abstract

Objective

This study investigated the neurocognitive characteristics of patients who visited an outpatient clinic requesting diagnosis and treatment for adult attention-deficit/hyperactivity disorder (ADHD).

Methods

The patients’ electronic medical records were retrospectively reviewed. Neurocognitive test results were compared using Student’s t-test according to their chief complaint, depressive symptoms, childhood history, and intelligence quotient (IQ). Neurocognitive characteristics affecting subjective symptoms of ADHD were analyzed by linear regression.

Results

The study included 106 patients. They did not have significant deficits in neurocognitive tests. Patients with depressive symptoms showed more impulsive responses (hit reaction time [p=0.037] and commission error [p=0.024]) and self-reported ADHD symptoms (p=0.001). Verbal (p=0.036) and visual memory (p=0.020) were significantly deficient in patients with a childhood ADHD diagnosis. Patients with a low IQ had significant deficits in various domains. Depressive symptoms and vigilance were significantly related to subjective symptoms of ADHD (adjusted R2=0.430, β=0.457, p=0.002).

Conclusion

Our results imply that the neurocognitive function of patients with subjective ADHD symptoms was not abnormal but was affected by depressive symptoms.

INTRODUCTION

With the emerging concept of attention-deficit/hyperactivity disorder (ADHD) as a lifelong problem [1], the prevalence of ADHD in the adult population is increasing [2]. According to data from Korean Health Insurance Review and Assessment Service, the rate of diagnosis of adult ADHD in Korea increased 10.1-fold from 2008 to 2018 [3]. The steep increase in the prevalence of adult ADHD in Korea can be attributed to increased awareness of the disorder and the extension of insurance coverage for ADHD medications in adults [3]. From 2015 to 2018, the number of adults newly prescribed medication for ADHD tripled in Korea [4]. Clinically, there is a growing trend of patients self-diagnosing with adult ADHD based on internet resources and seeking medication for this condition.

While patients may benefit from the treatment of adult ADHD, concerns about overdiagnosis and stimulant abuse persist [5-7]. Approximately 20% of college students in the US have been prescribed stimulants [8] and the non-prescribed use of stimulants is also prevalent [9]. Young adults experiencing stressful competitive academic environments and workplace burnout commonly experience cognitive problems that mimic ADHD symptoms [10-12], and they are thus tempted to use stimulants [6,13-15]. The potential for the diagnosis of adult ADHD to serve as a justification for stimulant use, which could detract from patient welfare, highlights the need for careful diagnosis and prescription in clinical psychiatry.

Adult ADHD is typically diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [16] or through criteria-based diagnostic interviews such as the Diagnostic Interview for ADHD in Adults (DIVA-5) [17]. Several self-rating scales are also used in the diagnosis, including the Adult ADHD Self-Report Scale (ASRS) [18], Barkley Adult ADHD Rating Scale-IV [19], and Conners Adult ADHD Rating Scales (CAARS) [20]. For the prescription of stimulants in Korea, an evaluation by a psychiatrist based on diagnostic criteria and the results of one or more ADHD self-rating scale are required. However, self-rating scales are susceptible to unreliable responses from individuals feigning ADHD [21,22] and are also prone to false positives among those seeking secondary gains and those who are malingering [23]. Recall bias may further complicate diagnosis [24]. Since the scale scores rely on patient reports, diagnoses are susceptible to patient expectations. Moreover, some experts argue that the DSM-5 criteria are too broad [5], leading to overdiagnosis of ADHD. Many psychiatric conditions involve attention deficits with subjective symptoms overlapping with those of ADHD [25-27], making current diagnostic criteria and self-rating scales inadequate for differentiating ADHD from other conditions [5].

Comprehensive methods are used for diagnosing ADHD, including school reports, parent reports, self-reports, diagnostic interviews, and neurocognitive tests [28]. In childhood, the first two methods play a decisive role. However, these sources of information are often unavailable for adult patients, who typically seek hospital care independently. This absence poses challenges for clinicians in collecting objective information from adult patients. Consequently, objective findings from neurocognitive tests may play a crucial role in comprehensive diagnostics. Previous studies have identified impairments in attention, vigilance, working memory, and executive functions as the core psychopathology of ADHD [29,30]. Although neurocognitive test results of adult ADHD patients show discernable deviations from those in healthy controls, the clinical utility of these tests for diagnosing ADHD has been questioned due to their low sensitivity and specificity [31-33]. Studies aiming to differentiate cognitive issues caused by depression from those caused by ADHD using neurocognitive tests have not found significant differences in performance-based measures [34]. Furthermore, consensus is lacking on which neurocognitive domain is most relevant to adult ADHD.

Previous studies have investigated the neurocognitive characteristics of individuals diagnosed with adult ADHD using operational criteria. However, given the limitations of diagnostic criteria and self-rating scales, the populations included in these studies may not accurately represent the conceptual definition of ADHD, which differs from operationally defined ADHD. This discrepancy could limit our understanding of the core psychopathology or cognitive characteristics of patients who report attentional problems.

Therefore, our study adopted a novel approach to examine the neurocognitive profiles of adult ADHD. Rather than using diagnostic interviews and self-rating scales to identify ADHD patients, this study enrolled all patients who sought diagnosis and treatment for ADHD at the outpatient clinic. Subjects were categorized according to their clinical characteristics, and their neurocognitive profiles were examined. Additionally, we analyzed the neurocognitive characteristics associated with the severity of subjective ADHD symptoms.

METHODS

Study population and data collection

This study included 106 patients who visited Seoul National University Hospital (SNUH) and completed the “SNUH adult ADHD battery” between January 2020 and December 2022. Patient data were collected retrospectively from the Seoul National University Hospital Patients Research Environment system and electronic medical records. Data were collected on demographics (age, sex, and years of education), socioeconomic status (marital status, living arrangements, type of medical insurance, occupation, and grades at school), history of childhood ADHD and other psychiatric diagnoses, history of stimulant and other psychiatric prescriptions, family history of ADHD and other psychiatric disorders, chief complaint leading to hospital referral, current psychiatric medication, and neurocognitive test results. This study was approved by the Institutional Review Board of SNUH (IRB no. 2212-054-1384). The IRB waived the requirement for informed consent prior to data extraction.

SNUH adult ADHD battery

A computerized neurocognitive battery was constructed using resources available at SNUH [35-37], i.e., age-and-sex specific normative values for each test. The battery is composed of tests that measure attention (auditory/visual attention span, Conners Continuous Performance Test [CCPT], and Trail Making Test [TMT] A), verbal memory (immediate recall, delayed recall, and delayed recognition), visual memory (immediate recall and delayed recognition) and executive function (Wisconsin Card Sorting Test, Stroop test, and TMT B) (Table 1). All tests have been standardized and tested for validity and reliability in the Korean population, and the results are presented as T-scores. Self-rated depression (Center for Epidemiologic Studies Depression Scale [CES-D]) and ADHD symptom (Korean Adult ADHD Scale [K-AADHDS]) scales were also completed, and intelligence quotient (IQ) was measured using the Korean Wechsler Adult Intelligence Scale–Fourth Edition.

Overview of neurocognitive tests used in this study

Components of the neurocognitive battery

Forward and backward auditory and visual attention span tasks were used to evaluate attention and working memory. Memory function, including encoding, storage, and retrieval, was evaluated in the verbal and visual domains. The TMT A/B was used to evaluate executive function and selective, focused, and divided attention. The Wisconsin Card Sorting Test and Stroop test were used to evaluate frontal lobe executive function.

The CCPT is widely used for diagnosing ADHD; this study used the third version of the instrument (CPT-3) [38]. The CPT-3 provides measures of different aspects of ADHD, including detectability (ability to discriminate between targets and non-targets), omission errors (failure to respond to the target), variability (response speed consistency), hit reaction time (HRT; mean response speed for correct responses), commission errors (incorrect responses to non-targets), perseveration (random, repetitive, or anticipatory responses), HRT block change (change in mean response speed across blocks), and HRT interstimulus interval (HRT ISI) change (change in mean response speed for various ISIs). Detectability, omission errors, commission errors, HRT, and variability are measures of inattentiveness. Measures of impulsivity include HRT, commission errors, and perseveration. HRT block change represents sustained attention, and HRT ISI change represents vigilance.

Self-reported ADHD scale

The K-AADHDS is the Korean adaptation of Murphy and Barkley’s Adult ADHD Scale [19], an 18-item questionnaire designed to assess inattention and hyperactivity/impulsivity. Its reliability and validity have been well-established for the Korean population [39]. While the original authors provided normative scores for this self-report measure [40], they noted that determining diagnostic thresholds for ADHD requires a careful approach and further research.

Self-reported depression scale

The CES-D was used to evaluate depressive symptoms. Originally developed by Radloff [41] and later translated into Korean [42], the CES-D is known for its high internal consistency, validity, and test–retest reliability. As a straightforward and effective tool for screening depression and exploring relationships among various variables, it is widely used in epidemiological studies [43].

Statistical analysis

The neurocognitive data were mainly analyzed in the following respects: 1) Deviation from norm values in all patients and subgroups and 2) Comparisons between the chief complaint of the ADHD group and the other chief complaint group; between patients with depressive symptoms (high CES-D score) and those without; between patients with and without a childhood (aged <12 years) diagnosis of ADHD; and between patients with and without a low IQ (below 85, the general cutoff point for borderline intellectual functioning).

Patients primarily reporting attentional problems and seeking diagnosis and treatment for adult ADHD were assigned to the “chief complaint of ADHD” group. Patients primarily reporting other symptoms (predominantly depressive mood) but also seeking a diagnosis of ADHD were assigned to the “other complaints” group.

Demographic and neurocognitive test results were compared between groups using the chi-square test and Student’s t-test. Bonferroni correction was used to correct for multiple comparisons. Correlations between self-reported ADHD scale scores and other neurocognitive scores were analyzed using Pearson correlation. Factors that showed correlations were included in stepwise multiple linear regression analysis to identify factors influencing self-reported ADHD scale scores. All statistical analyses were performed using SPSS software (ver. 25.0; IBM Corp., Armonk, NY, USA).

RESULTS

Patient characteristics

Table 2 summarizes the characteristics of the 106 patients included in the study (56.6% males; mean age at first visit, 26.6±8.0 years). Among the patients, 46 had a chief complaint of an attention problem, and 86 had CES-D scores above the cutoff for depression. The mean years of education was 13.8±2.1 and the unemployment rate was 31.1%. Among the patients whose school grades were recorded, more than half had low grades. One-fifth (21.7%) of the subjects were diagnosed with ADHD at childhood, and 18.9% had a history of stimulant therapy during childhood. In adulthood, 37.7% of the patients had a history of stimulant therapy and 23.6% were taking stimulants at the first visit.

Demographic characteristics of the patients

Patients with chief complaints other than an attention problem had a higher probability of taking psychotropic medications (p<0.001). This was also seen for patients with high CES-D scores (p=0.002). Patients with a childhood ADHD diagnosis were younger (p<0.001) and less educated (p<0.001). They also had a more extensive family history of ADHD (p=0.028). Significantly more patients with a low IQ were unemployed (p=0.035).

Neurocognitive test results

Table 3 shows the patients’ average T-scores for the neurocognitive tests and the raw scores of the self-reported assessments. The majority of the T-scores were in the normal range. Verbal immediate recall was the only parameter for which the score was lower in the patients compared to the age-and-sexmatched norms (mean±standard deviation [SD]=40.57± 9.94). The patients outperformed the norm in visual immediate recall (mean±SD=67.20±8.95).

Comparisons of neurocognitive test results by group

There was no significant difference in neurocognitive parameters between the chief complaint of ADHD and other complaints groups, except for the CES-D score (p=0.022). The T-score for HRT was significantly lower (p=0.037), and that of commission errors was higher, in patients with high CES-D scores (>16) compared to those with low scores (p=0.024). This indicates that more depressed patients were more inattentive and impulsive during the test. The K-AADHDS score was also significantly higher in depressed patients (p=0.001). Verbal (p=0.036) and visual memory (p=0.020) were significantly deficient in patients with a childhood diagnosis of ADHD. Patients with a low IQ performed worse on the attention span test, TMT, verbal memory, and Wisconsin Card Sorting Test, while there were no significant differences between the normal and low IQ groups in the CPT-3, Stroop test, or self-reported assessments.

Relationship between neurocognitive test results and self-rating scores

Overall, the K-AADHDS total score was significantly correlated with the CPT-3 and Stroop test subscale scores (Table 4). The K-AADHDS inattention and impulsivity/hyperactivity subscale scores showed a similar pattern of results. The inattention subscale score was correlated with the total IQ score (r=-0.328), perceptual reasoning subscale score (r=-0.376, p=0.048), and working-memory subscale score (r=-0.426, p=0.024). A similar pattern of correlations was found between the CES-D score and neurocognitive test results. The CES-D score was correlated with detectability (r=0.241, p=0.014), commission errors (r=0.295, p=0.003), and Stroop test performance. Moreover, the CES-D and K-AADHDS scores were highly correlated (r=0.367, p<0.001).

Correlations between self-reported symptoms and neurocognitive parameters (N=106)

In multivariate linear regression, the CES-D total score and HRT ISI change were significantly associated with K-AADHDS variables (Table 5) (adjusted R2=0.430, β=0.457, p=0.002). Conversely, subjective inattentive symptoms of K-AADHDS were significantly associated with the CES-D total score (adjusted R2=0.278, β=0.547, p=0.001).

Neurocognitive parameters significantly associated with the K-AADHDS score according to stepwise multivariate linear regression

DISCUSSION

The results of this study indicate that in patients complaining of attention problems, many of the neurocognitive functions were not significantly impaired. The neurocognitive parameters also did not differ significantly according to the chief complaint during clinical visits. Individuals exhibiting more depressive symptoms showed more inattentive and impulsive responses on neurocognitive tests. IQ was related to deficits in various neurocognitive tests. Depressive symptoms and measures of vigilance were strongly associated with subjective ADHD symptoms.

The results indicate that patients purportedly suffering from ADHD do not exhibit significant attentional deficits in objective tests. Individuals with greater depressive symptoms had poorer performance in terms of HRT and made more commission errors. Previous studies using the CCPT suggested that it is not useful for distinguishing ADHD from other disorders [44,45]. Patients with depression tend to underperform on various neurocognitive tests, particularly those requiring sustained effort [46,47]. While attention and impulsivity are central to ADHD, they can also be influenced by mood.

This study found a correlation between changes in HRT ISI and self-reported ADHD symptoms. This aligns with previous studies that showed associations between HRT ISI and self-reported hyperactivity/impulsivity and inattentiveness [48,49]. However, vigilance can be affected by a variety of psychiatric conditions, including mood disorders, schizophrenia, and sleep–wake cycle disorders [50], with depression notably linked to decreased vigilance [51]. Given that vigilance can be affected by general psychiatric conditions, it is difficult to assert that vigilance is a specific characteristic associated with adult ADHD.

Previous studies have indicated that mood disorders frequently co-occur with adult ADHD [52,53]. Retrospective studies have found that 35%–50% of adult ADHD patients exhibit depressive symptoms [54]. These conditions may share a common risk factor; depression may develop as a result of ADHD-related impairments, or the observed overlap may stem from shared symptoms and diagnostic challenges [55-57]. The DSM-5 advises that the diagnosis of ADHD should be made when inattentive symptoms cannot be fully accounted for by other mental disorders. However, due to overlapping symptoms, it remains unclear whether these disorders are distinct entities or represent a single condition. The self-rating scales used in this study showed that individuals with profound depression perceived their attentional issues as more severe; this aligns with Harrison et al. [10], who found a significant association between depression and ADHD in university students. Bodenburg et al. [58], found that self-reported ADHD symptoms did not correlate with executive function or attention, but rather with a negative response bias influenced by negative cognitions in depressive patients. Our study showed no significant neurocognitive deficits in individuals reporting attentional problems. Moreover, neurocognitive test outcomes did not differ between individuals seeking treatment for depression versus attention. Clinically, patients reporting severe attentional problems in daily life but showing normal neurocognitive test performance may be experiencing a negative cognitive bias.

Qualitative studies report that patients perceive a positive impact of an ADHD diagnosis on identity and life aspects [59]. Korean patients experienced great relief upon learning their past difficulties were attributable to ADHD and that solutions exist [60]. In contrast, a diagnosis of depression often carries stigma and perceptions of personal weakness [61]. Thus, there is a tendency to attribute cognitive issues to ADHD and self-diagnose accordingly. These findings, alongside our study results, support the notion that late-onset ADHD might be considered a variant of depression, with clinicians potentially misdiagnosing cognitive changes associated with depression as ADHD due to their similar presentations [62]. Accordingly, the use of psychostimulants among students is closely tied to traditional middle-class values surrounding academic performance [63], suggesting that an ADHD diagnosis may medicalize underperformance in an achievement-oriented society [7].

Our results suggest that IQ affects various cognitive domains, including attention [64]. Adults with ADHD were found to have a lower full-scale IQ in a meta-analysis [65,66]. Individuals with intellectual disability may perform less well in neurocognitive tests [67]. The proportion of children meeting the DSM criteria for ADHD was significantly higher in a borderline intellectual functioning group [68]. However, diagnosing ADHD in individuals with intellectual disabilities remains controversial [69-71]. While stimulants may impact IQ scores, they do not necessarily improve intelligence [72]. Additionally, a lower IQ has been linked to a less favorable response to methylphenidate in ADHD patients [73,74]. The overlap between low intelligence and ADHD symptoms, coupled with the stigma associated with intellectual disability, may lead individuals to prefer a diagnosis of ADHD, which is perceived as a condition that can be improved. Therefore, assessing an individual’s intellectual function alongside ADHD is crucial for appropriate intervention.

Patients with a childhood diagnosis of ADHD have similar self-reported symptoms to those with adult ADHD, but show deficiencies in verbal and visual memory function. Working memory is gaining attention as a potential core deficit or endophenotype of ADHD, with deficits persisting into adulthood [75,76]. This study found that patients with and without a childhood diagnosis differed in working memory function, supporting the notion that early and late-onset ADHD are dissociable disease entities [62].

The results of this study raise a fundamental question: “What is adult ADHD?” The concept of ADHD has evolved over time, and operational diagnostic systems have changed accordingly [77]. The initial description of inattentive and problematic children by Still [78] differs greatly from the criteria outlined in the DSM-5. Operational diagnoses represent a consensus among specialists rather than an absolute depiction of reality, serving the needs of clinical medicine. Thus, the concept of adult ADHD is justifiable only to the extent that it facilitates effective treatment. Since the symptoms of ADHD are issues in daily living, evaluations are contextualized within everyday life scenarios. Our findings indicate that neurocognitive tests, despite being objective, may not be useful in adults. Treatment efficacy is assessed mainly through patient self-reports, which have inherent limitations. The therapeutic agents for ADHD, including stimulants and atomoxetine, are monoamine-augmenting drugs potentially effective in alleviating depression [79], which frequently co-occurs with ADHD. This may explain the success of treatment in adulthood ADHD.

Some scholars advocate for a deeper examination of the diagnostic criteria of ADHD and emphasize the importance of understanding the complexity of the condition [7]. A dimensional approach and spectrum model have been proposed for ADHD symptomatology [55,80]. Our findings indicate that diagnosing adult ADHD in clinical practice requires careful consideration, and further research and discussions are necessary to delineate the condition known as “adult ADHD.”

To our knowledge, this is the first study to analyze the characteristics of patients complaining of attention problems in a natural setting and to compare the characteristics of clinically distinct groups. Our approach can be distinguished from other studies that included operationally defined participants, which may elicit a systematic bias. By including all patients who visited the clinic with symptoms, this research offers a comprehensive view of attentive disorder, which is a new diagnosis surrounded by controversy. Additionally, this study integrated clinical information and the results of standardized tests covering various aspects of cognition.

However, there were some limitations to this study. First, it used data retrospectively collected at a single institution. SNUH is a tertiary hospital primarily treating patients referred from primary and secondary hospitals. Thus, the study population might not represent the broader patient population. Second, the results showed the importance of IQ in the neurocognitive function of attention, but only 34.9% of the patients underwent IQ testing. Due to the limited sample size, the associations of IQ with other neurocognitive tests and self-reported ADHD scales were low, and the contribution of IQ to ADHD symptoms might have been overlooked. Third, although the study collected data on current use of medication, the use of stimulants on the day of the test varied among participants, potentially affecting the study’s outcomes. Lastly, the data were insufficient to identify a causal relationship between adult ADHD and depression, suggesting the need for further research to explore their connection.

This study identified the neurocognitive characteristics of individuals visiting the hospital with symptoms of adult ADHD. This research may contribute to the understanding of the condition known as “adult ADHD” and its diagnosis.

Notes

Availability of Data and Material

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors have no potential conflicts of interest to disclose.

Author Contributions

Conceptualization: Ung Gu Kang, Seon Young Park, Yoosuk An. Data curation: Seon Young Park. Formal analysis: Seon Young Park, Yoosuk An, Sunghyun Park. Investigation: Seon Young Park. Methodology: Ung Gu Kang, Min-Sup Shin, Seon Young Park. Project administration: Seon Young Park. Resources: Ung Gu Kang, Min-Sup Shin. Software: Seon Young Park, Sunghyun Park. Supervision: Ung Gu Kang, Min-Sup Shin. Validation: Seon Young Park, Yoosuk An. Visualization: Seon Young Park. Writing—original draft: Seon Young Park. Writing—review & editing: all authors.

Funding Statement

None

Acknowledgements

None

References

1. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993;50:565–576.
2. Chung W, Jiang SF, Paksarian D, Nikolaidis A, Castellanos FX, Merikangas KR, et al. Trends in the prevalence and incidence of attention-deficit/hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA Netw Open 2019;2e1914344.
3. Seo JC, Jon DI, Shim SH, Sung HM, Woo YS, Hong J, et al. Prevalence and comorbidities of attention deficit hyperactivity disorder among adults and children/adolescents in Korea. Clin Psychopharmacol Neurosci 2022;20:126–134.
4. Lee SM, Cheong HK, Oh IH, Hong M. Nationwide rate of adult ADHD diagnosis and pharmacotherapy from 2015 to 2018. Int J Environ Res Public Health 2021;18:11322.
5. Paris J, Bhat V, Thombs B. Is adult attention-deficit hyperactivity disorder being overdiagnosed? Can J Psychiatry 2015;60:324–328.
6. Bordoff B. The challenges and limitations of diagnosing and pharmacologically treating ADHD in university students. Psychol Inj Law 2017;10:114–120.
7. Gascon A, Gamache D, St-Laurent D, Stipanicic A. Do we over-diagnose ADHD in North America? A critical review and clinical recommendations. J Clin Psychol 2022;78:2363–2380.
8. McCabe SE, West BT, Teter CJ, Boyd CJ. Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013: connecting the dots. Addict Behav 2014;39:1176–1182.
9. Novak SP, Håkansson A, Martinez-Raga J, Reimer J, Krotki K, Varughese S. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry 2016;16:274.
10. Harrison AG, Alexander SJ, Armstrong IT. Higher reported levels of depression, stress, and anxiety are associated with increased endorsement of ADHD symptoms by postsecondary students. Can J Sch Psychol 2013;28:243–260.
11. Shin YC. Job stress and depression. J Korean Neuropsychiatr Assoc 2020;59:88–97.
12. Lee SY. Understanding and management of burnout. J Korean Neuropsychiatr Assoc 2020;59:105–114.
13. Arria AM, Geisner IM, Cimini MD, Kilmer JR, Caldeira KM, Barrall AL, et al. Perceived academic benefit is associated with nonmedical prescription stimulant use among college students. Addict Behav 2018;76:27–33.
14. Dupont RL, Coleman JJ, Bucher RH, Wilford BB. Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict 2008;17:167–171.
15. Weyandt LL, Janusis G, Wilson KG, Verdi G, Paquin G, Lopes J, et al. Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables. J Atten Disord 2009;13:284–296.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) Arlington: American Psychiatric Publishing; 2013.
17. Kooij JJS, Francken MH. Diagnostic interview for ADHD in adults (DIVA) Hague: DIVA Foundation; 2010.
18. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, et al. The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005;35:245–256.
19. Barkley RA. Barkley adult ADHD rating scale-IV (BAARS-IV) New York: Guilford Press; 2011.
20. Erhardt D, Epstein JN, Conners CK, Parker JDA, Sitarenios G. Self-ratings of ADHD symptomas in auts II: reliability, validity, and diagnostic sensitivity. J Atten Disord 1999;3:153–158.
21. Suhr J, Hammers D, Dobbins-Buckland K, Zimak E, Hughes C. The relationship of malingering test failure to self-reported symptoms and neuropsychological findings in adults referred for ADHD evaluation. Arch Clin Neuropsychol 2008;23:521–530.
22. Fuermaier ABM, Tucha O, Koerts J, Butzbach M, Weisbrod M, Aschenbrenner S, et al. Susceptibility of functional impairment scales to noncredible responses in the clinical evaluation of adult ADHD. Clin Neuropsychol 2018;32:671–680.
23. Vizgaitis AL, Bottini S, Polizzi CP, Barden E, Krantweiss AR. Self-reported adult ADHD symptoms: evidence supporting cautious use in an assessment-seeking sample. J Atten Disord 2023;27:1156–1166.
24. von Wirth E, Mandler J, Breuer D, Döpfner M. The accuracy of retrospective recall of childhood ADHD: results from a longitudinal study. J Psychopathol Behav Assess 2021;43:413–426.
25. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792–1798.
26. Edebol H, Helldin L, Norlander T. Objective measures of behavior manifestations in adult ADHD and differentiation from participants with bipolar II disorder, borderline personality disorder, participants with disconfirmed ADHD as well as normative participants. Clin Pract Epidemiol Ment Health 2012;8:134–143.
27. Sibley MH, Rohde LA, Swanson JM, Hechtman LT, Molina BSG, Mitchell JT, et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry 2018;175:140–149.
28. Nikolas MA, Marshall P, Hoelzle JB. The role of neurocognitive tests in the assessment of adult attention-deficit/hyperactivity disorder. Psychol Assess 2019;31:685–698.
29. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 2004;18:485–503.
30. Stefanatos GA, Baron IS. Attention-deficit/hyperactivity disorder: a neuropsychological perspective towards DSM-V. Neuropsychol Rev 2007;17:5–38.
31. Schoechlin C, Engel RR. Neuropsychological performance in adult attention-deficit hyperactivity disorder: meta-analysis of empirical data. Arch Clin Neuropsychol 2005;20:727–744.
32. Wasserman T, Wasserman LD. The sensitivity and specificity of neuropsychological tests in the diagnosis of attention deficit hyperactivity disorder. Appl Neuropsychol Child 2012;1:90–99.
33. Pagán AF, Huizar YP, Schmidt AT. Conner’s continuous performance test and adult ADHD: a systematic literature review. J Atten Disord 2023;27:231–249.
34. Paucke M, Stibbe T, Huang J, Strauss M. Differentiation of ADHD and depression based on cognitive performance. J Atten Disord 2021;25:920–932.
35. Ha KS, Kwon JS, Lyoo IK. Development and standardization of the computerized attention assessment for Korean adults. J Korean Neuropsychiatr Assoc 2002;41:335–346.
36. Ha KS, Kwon JS, Lyoo IK, Kong SW, Lee DW, Youn T. Development and standardization process, and factor analysis of the computerized cognitive function test system for Korea adults. J Korean Neuropsychiatr Assoc 2002;41:551–562.
37. Lyoo IK, Kwon JS, Ha KS. Development and standardization of the computerized higher cortical function assessment for Korean adults. J Korean Neuropsychiatr Assoc 2002;41:538–550.
38. Conners CK. Conners continuous performance test 3rd edition (conners CPT 3) & connors continuous auditory test of attention (conners CATA): technical manual Toronto: MHS; 2014.
39. Kim E. [The validation of Korean adult ADHD scale (K-AADHDS)]. Kor J Clin Psychol 2003;22:897–911. Korean.
40. Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1996;1:147–161.
41. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385–401.
42. Cho MJ, Kim KH. Use of the center for epidemiologic studies depression (CES-D) scale in Korea. J Nerv Ment Dis 1998;186:304–310.
43. Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for depression in the general population with the center for epidemiologic studies depression (CES-D): a systematic review with meta-analysis. PLoS One 2016;11e0155431.
44. Advokat C, Martino L, Hill BD, Gouvier W. Continuous performance test (CPT) of college students with ADHD, psychiatric disorders, cognitive deficits, or no diagnosis. J Atten Disord 2007;10:253–256.
45. Baggio S, Hasler R, Giacomini V, El-Masri H, Weibel S, Perroud N, et al. Does the continuous performance test predict ADHD symptoms severity and ADHD presentation in adults? J Atten Disord 2020;24:840–848.
46. Mohn C, Rund BR. Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints. BMC Psychiatry 2016;16:108.
47. Hammers DB, Weisenbach S. Questioning the effort hypothesis that depressed patients perform disproportionately worse on effortful cognitive tasks. Percept Mot Skills 2020;127:401–414.
48. Solanto MV, Etefia K, Marks DJ. The utility of self-report measures and the continuous performance test in the diagnosis of ADHD in adults. CNS Spectr 2004;9:649–659.
49. Cohen AL, Shapiro SK. Exploring the performance differences on the flicker task and the conners’ continuous performance test in adults with ADHD. J Atten Disord 2007;11:49–63.
50. Ballard JC. Computerized assessment of sustained attention: a review of factors affecting vigilance performance. J Clin Exp Neuropsychol 1996;18:843–863.
51. Byrne DG. Vigilance and arousal in depressive states. Br J Soc Clin Psychol 1976;15:267–274.
52. Sandstrom A, Perroud N, Alda M, Uher R, Pavlova B. Prevalence of attention-deficit/hyperactivity disorder in people with mood disorders: a systematic review and meta-analysis. Acta Psychiatr Scand 2021;143:380–391.
53. Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716–723.
54. Sobanski E. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2006;256(Suppl 1):i26–i31.
55. Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry 2017;17:302.
56. Comparelli A, Polidori L, Sarli G, Pistollato A, Pompili M. Differentiation and comorbidity of bipolar disorder and attention deficit and hyperactivity disorder in children, adolescents, and adults: a clinical and nosological perspective. Front Psychiatry 2022;13:949375.
57. Frías Á, Palma C, Farriols N. Comorbidity in pediatric bipolar disorder: prevalence, clinical impact, etiology and treatment. J Affect Disord 2015;174:378–389.
58. Bodenburg S, Wendiggensen J, Kasten E. Scores in self-report questionnaires assessing adult ADHD can be influenced by negative response bias but are unrelated to performance on executive function and attention tests. Psychol Inj Law 2022;15:189–199.
59. Hansson Halleröd SL, Anckarsäter H, Råstam M, Hansson Scherman M. Experienced consequences of being diagnosed with ADHD as an adult - a qualitative study. BMC Psychiatry 2015;15:31.
60. Lee SJ. [Research into the experiences of before and after adult ADHD diagnosis: interpretative phenomenological analysis]. Korean J Couns 2017;18:111–131. Korean.
61. Cho HJ, Yim HW, Hyun MH, Jo SJ, Ji YN, Jun TY, et al. [A study of the attitudes toward depression in general population]. Korean J Stress Res 2008;16:233–240. Korean.
62. Riglin L, Wootton RE, Livingston LA, Agnew-Blais J, Arseneault L, Blakey R, et al. “Late-onset” ADHD symptoms in young adulthood: is this ADHD? J Atten Disord 2022;26:1271–1282.
63. Kerley KR, Copes H, Griffin OH. Middle-class motives for non-medical prescription stimulant use among college students. Deviant Behav 2015;36:589–603.
64. Jepsen JR, Fagerlund B, Mortensen EL. Do attention deficits influence IQ assessment in children and adolescents with ADHD? J Atten Disord 2009;12:551–562.
65. Bridgett DJ, Walker ME. Intellectual functioning in adults with ADHD: a meta-analytic examination of full scale IQ differences between adults with and without ADHD. Psychol Assess 2006;18:1–14.
66. Frazier TW, Demaree HA, Youngstrom EA. Meta-analysis of intellectual and neuropsychological test performance in attention-deficit/hyperactivity disorder. Neuropsychology 2004;18:543–555.
67. Celeste PM, Esteban VP, Mariana L, María José GB, Florencia B, Christy E, et al. Continuous performance test in children with intellectual disability and attention deficit hyperactivity disorder. Appl Neuropsychol Child 2019;8:246–252.
68. Peña-Salazar C, Arrufat F, Santos JM, Novell R, Valdés-Stauber J. Psychopathology in borderline intellectual functioning: a narrative review. Adv Ment Health Intellect Disabil 2018;12:22–33.
69. Antshel KM, Phillips MH, Gordon M, Barkley R, Faraone SV. Is ADHD a valid disorder in children with intellectual delays? Clin Psychol Rev 2006;26:555–572.
70. Deutsch CK, Dube WV, McIlvane WJ. Attention deficits, attention-deficit hyperactivity disorder, and intellectual disabilities. Dev Disabil Res Rev 2008;14:285–292.
71. Reilly C, Holland N. Symptoms of attention deficit hyperactivity disorder in children and adults with intellectual disability: a review. J Appl Res Intellect Disabil 2011;24:291–309.
72. Zhang L, Jin X, Zhang Y. Effect of methylphenidate on intelligence quotient scores in Chinese children with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2011;31:51–55.
73. Tarrant N, Roy M, Deb S, Odedra S, Retzer A, Roy A. The effectiveness of methylphenidate in the management of attention deficit hyperactivity disorder (ADHD) in people with intellectual disabilities: a systematic review. Res Dev Disabil 2018;83:217–232.
74. Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharmacol 2003;13:29–40.
75. Alderson RM, Kasper LJ, Hudec KL, Patros CH. Attention-deficit/hyperactivity disorder (ADHD) and working memory in adults: a metaanalytic review. Neuropsychology 2013;27:287–302.
76. Hong JS, Lee YS, Hong M, Kim B, Joung YS, Yoo HK, et al. Cognitive developmental trajectories in adult ADHD patients and controls: a comparative study. J Atten Disord 2022;26:391–407.
77. An Y, Song Y, Kang UG. [A conceptual review on ADHD and adult ADHD (1): historical change of ADHD-based on the DSM]. J Korean Neuropsychiatr Assoc 2022;61:11–27. Korean.
78. Still GF. The Goulstonian Lectures ON SOME ABNORMAL PSYCHICAL CONDITIONS IN CHILDREN. Lancet 1902;159:1008–1013.
79. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry 1998;59(Suppl 5):60–63. discussion 64.
80. Heidbreder R. ADHD symptomatology is best conceptualized as a spectrum: a dimensional versus unitary approach to diagnosis. Atten Defic Hyperact Disord 2015;7:249–269.

Article information Continued

Table 1.

Overview of neurocognitive tests used in this study

Neurocognitive function Tests Measures
Attention Attention Span Test (forward) Auditory
Visual
Conners’ CPT-3 Inattentiveness: detectability, omissions, commissions, HRT, variability
Impulsivity: HRT, commissions, perseverations
Sustained attention: HRT block change
Vigilance: HRT ISI change
Working memory Verbal Memory Test Immediate recall A1, A5, A1–5, (delayed recall, delayed recognition)
Visual Memory Test Immediate recall A1, A5, A1–5, (delayed recognition)
Attention Span Test (backward) Auditory
Visual
Frontal lobe executive function Trail Making Test A Selective/focused attention
Trail Making Test B Divided attention
Wisconsin Card Sorting Test Total trials, total errors, perseverative responses/errors, non-perseverative errors
Stroop test Word, color only, color word, word of color word, color of color word

CPT, Continuous Performance Test; HRT, hit reaction time; HRT ISI, HRT interstimulus interval

Table 2.

Demographic characteristics of the patients

Characteristics All patients (N=106) Chief complaint of ADHD (N=46) Other chief complaints (N=60) p No depression (CES-D<16) (N=17) Depression (CES-D≥16) (N=86) p No childhood ADHD diagnosis (N=82) Childhood ADHD diagnosis (N=23) p Low IQ (IQ<85) (N=12) Normal IQ (IQ≥85) (N=25) p
Male 60 (56.6) 30 (65.2) 30 (50.0) 0.121 12 (70.6) 48 (53.9) 0.259 44 (53.6) 17 (73.9) 0.082 6 (50.0) 16 (64.0) 0.417
Age (yr) 26.6±8.0 26.8±8.0 26.5±8.0 0.857 26.94±7.20 26.51±7.65 0.722 28.2±7.8 22.1±4.5 <0.001* 22.0±5.1 24.6±6.4 0.227
Years of education (yr) 13.8±2.1 13.9±2.0 13.7±2.2 0.486 13.82±2.24 13.71±2.06 0.206 14.1±2.1 12.5±1.4 <0.001* 12.5±1.2 13.2±2.1 0.326
Highly educated 36 (34.0) 17 (37.0) 19 (31.7) 0.373 5 (29.4) 29 (33.7) 0.730 31 (37.8) 1 (4.4) 0.001* 6 (24.0) 1 (8.3) 0.255
Medicaid 5 (4.7) 3 (6.5) 2 (3.3) 0.443 0 (0) 5 (5.8) 0.308 5 (6.1) 0 (0) 0.225 0 (0) 1 (4.0) 0.482
Married 4 (3.8) 2 (4.3) 2 (3.3) 0.759 0 (0) 4 (4.7) 0.388 3 (3.7) 1 (4.4) 0.882 0 (0) 1 (4.2) 0.473
Living alone 18 (17.0) 9 (19.6) 9 (15.0) 0.286 4 (23.5) 14 (16.3) 0.427 17 (20.7) 1 (4.4) 0.048* 2 (18.2) 1 (5.0) 0.235
Occupation
 Unemployed 33 (31.1) 9 (19.6) 24 (40.0) 0.113 4 (23.5) 28 (32.6) 0.491 26 (31.7) 7 (30.4) 0.189 6 (50.0) 2 (8.0) 0.035*
 Student 36 (34.0) 17 (37.0) 19 (31.7) 5 (29.4) 31 (36.0) 24 (29.3) 12 (52.2) 4 (33.3) 14 (56.0)
 Full-time job 22 (20.8) 13 (28.3) 9 (15.0) 5 (29.4) 15 (17.4) 11 (13.4) 1 (4.4) 1 (8.3) 4 (16.0)
 Part-time job 15 (14.2) 7 (15.2) 8 (13.3) 3 (17.6) 12 (14.0) 21 (25.6) 3 (13.0) 1 (8.3) 5 (20.0)
 Frequent occupation change 15 (14.2) 7 (15.2) 8 (13.3) 0.665 3 (17.6) 11 (12.8) 0.634 12 (14.6) 3 (13.0) 0.839 2 (18.2) 4 (16.0) 0.871
Grade in school-time
 Low 30 (28.3) 16 (34.8) 14 (23.3) 0.210 3 (17.6) 27 (31.4) 0.435 23 (28.0) 7 (30.4) 0.189 8 (88.9) 9 (56.3) 0.223
 Moderate 15 (14.2) 5 (10.9) 10 (16.7) 3 (17.6) 10 (11.6) 9 (11.0) 6 (26.1) 1 (11.1) 5 (31.3)
 High 12 (11.3) 8 (17.4) 4 (6.7) 1 (5.9) 11 (12.8) 10 (12.2) 1 (4.4) 0 (0) 2 (12.5)
 Unknown 49 (46.2) 17 (37.0) 32 (53.3) 10 (58.8) 38 (44.2) 40 (48.8) 9 (39.1) 3 (25.0) 9 (36.0)
Referral route
 Self 66 (62.3) 30 (65.2) 36 (60.0) 0.702 8 (47.1) 55 (64.0) 0.389 55 (67.1) 10 (43.5) 0.112 5 (41.4) 14 (56.0) 0.300
 Professional recommendation 20 (18.9) 7 (15.2) 13 (21.7) 5 (29.4) 15 (17.4) 14 (17.1) 6 (26.1) 4 (33.3) 3 (12.0)
 Family recommendation 20 (18.9) 9 (19.6) 11 (18.3) 4 (23.5) 16 (18.6) 13 (15.9) 7 (30.4) 3 (25.0) 9 (32.0)
Childhood medical history
 ADHD diagnosis 23 (21.7) 11 (23.9) 12 (20.0) 0.586 4 (23.5) 18 (20.9) 0.830 0 (0) 23 (100) <0.001* 4 (33.3) 9 (36.0) 0.874
 Stimulant medication 20 (18.9) 8 (17.4) 12 (20.0) 0.774 4 (23.5) 15 (17.4) 0.570 0 (0) 20 (87.0) <0.001* 4 (33.3) 9 (36.0) 0.874
 Other NP medication 23 (21.7) 8 (17.4) 15 (25.0) 0.376 5 (29.4) 18 (20.9) 0.458 10 (12.2) 13 (56.5) <0.001* 5 (41.7) 6 (24.0) 0.271
Adulthood medical history
 Stimulant medication 40 (37.7) 18 (39.1) 22 (36.7) 0.795 6 (35.3) 32 (37.2) 0.881 31 (37.8) 9 (39.1) 0.908 3 (25.0) 8 (32.0) 0.663
 Other NP medication 69 (65.1) 17 (37.0) 52 (86.7) <0.001* 6 (35.3) 62 (72.1) 0.003* 57 (69.5) 12 (52.2) 0.122 7 (58.3) 13 (52.0) 0.717
 Current NP medication 59 (55.7) 13 (28.3) 46 (76.7) <0.001* 4 (23.5) 55 (64.0) 0.002* 49 (59.8) 10 (43.5) 0.164 8 (66.7) 10 (40.0) 0.129
 Stimulant 25 (23.6) 12 (26.1) 13 (21.7) 0.595 3 (17.6) 20 (23.3) 0.612 20 (24.4) 5 (21.8) 0.792 1 (8.3) 7 (28.0) 0.174
 Antipsychotics 38 (35.8) 9 (19.6) 29 (48.3) 0.002* 1 (5.9) 37 (43.0) 0.004* 28 (34.1) 10 (43.5) 0.410 4 (33.3) 8 (32.0) 0.935
 Antidepressant 34 (32.1) 8 (17.4) 26 (43.3) 0.005* 3 (17.6) 31 (36.0) 0.140 30 (36.6) 4 (17.4) 0.082 5 (41.7) 4 (16.0) 0.088
 Mood stabilizer 23 (21.7) 4 (8.7) 19 (31.7) 0.004* 0 (0) 23 (26.7) 0.016* 18 (22.0) 5 (21.7) 0.983 3 (25.0) 7 (28.0) 0.847
 Benzodiazepine 27 (25.5) 6 (13.0) 21 (35.0) 0.010* 1 (5.9) 26 (29.2) 0.037* 22 (26.8) 5 (21.7) 0.622 2 (16.7) 6 (24.0) 0.612
Family history
 ADHD 5 (4.7) 4 (8.7) 1 (1.7) 0.061 1 (5.9) 4 (4.7) 0.855 2 (2.4) 3 (13.0) 0.028* 1 (8.3) 1 (4.0) 0.555
 Other psychiatric disorders 31 (29.2) 11 (23.9) 20 (33.3) 0.532 5 (29.4) 26 (30.2) 0.872 22 (26.8) 9 (39.1) 0.184 5 (41.6) 7 (28.0) 0.325

Values are presented as number (%) or mean±standard deviation. Statistics was analyzed using chi-square test for the categorical variables and Student’s t-test for the continuous variables.

*

statistically significant (p<0.05).

ADHD, attention-deficit/hyperactivity disorder; CES-D, Center for Epidemiologic Studies Depression Scale; IQ, intelligence quotient; NP, neuropsychiatric

Table 3.

Comparisons of neurocognitive test results by group

All patients (N=106) Chief complaint of ADHD (N=46) Other chief complaint (N=60) t p No Depression (CES-D<16) (N=17) Depression (CES-D≥16) (N=86) t p No childhood ADHD diagnosis (N=82) Childhood ADHD diagnosis (N=23) t p Low IQ (IQ<85) (N=12) Normal IQ (IQ≥85) (N=25) t p
Attention span test
 Forward (auditory) 55.03±15.56 57.37±16.26 53.23±14.89 -1.362 0.182 55.59±16.77 54.91±15.41 0.164 0.870 55.49±15.55 53.96±16.00 0.415 0.679 45.17±10.38 58.32±17.32 2.872 0.007*
 Backward (auditory) 52.45±12.13 55.96±12.54 49.77±11.18 -2.680 0.009* 53.35±11.92 52.22±12.04 0.355 0.723 52.94±11.54 50.96±14.38 0.688 0.493 42.33±8.97 56.84±13.77 3.315 0.002*
 Forward (visual) 49.67±10.71 51.52±11.34 48.25±10.06 -1.570 0.119 53.71±10.95 49.14±10.49 1.629 0.106 50.10±10.81 48.22±10.66 0.739 0.462 45.67±8.57 50.44±11.54 1.270 0.212
 Backward (visual) 45.47±11.16 46.70±12.11 44.53±10.38 -0.989 0.325 46.82±9.65 44.87±11.12 0.674 0.502 46.21±11.47 42.57±9.85 1.385 0.169 40.33±4.96 47.28±14.05 1.654 0.035*
Visual TMT
 TMT-A (selective/focused) 59.10±12.33 60.83±13.11 57.78±11.63 -1.263 0.209 62.06±14.09 58.47±11.80 1.111 0.269 60.01±12.21 55.09±11.92 1.718 0.089 50.33±9.70 58.08±15.37 1.863 0.072*
 TMT-B (divided) 55.66±12.93 57.93±13.41 53.88±12.37 -1.606 0.111 57.18±12.30 55.35±13.05 0.531 0.597 56.49±12.51 51.78±13.52 1.566 0.120 49.83±13.65 58.88±12.72 1.978 0.056
Conners’ CPT-3
 Measures of inattentiveness
  Detectability 46.90±10.16 46.74±10.19 47.02±10.22 0.139 0.890 42.35±10.83 47.62±9.95 -1.964 0.052 46.00±10.06 49.70±10.23 -1.551 0.124 52.00±12.87 45.68±8.59 -1.777 0.084
  Omission errors§ 48.84±9.31 49.22±10.14 48.55±8.70 -0.364 0.716 48.12±10.99 48.92±9.04 -0.322 0.748 47.73±7.82 52.00±12.58 -1.999 0.048 55.58±16.85 47.44±4.19 -1.650 0.126
  Variability§ 46.75±9.54 46.72±7.98 46.77±10.64 0.026 0.979 46.41±12.46 46.85±9.09 -0.170 0.866 45.87±9.64 49.57±8.86 -1.654 0.101 49.67±14.91 47.12±7.50 -0.696 0.491
 Measures of impulsivity
  HRT 53.57±9.17 54.24±9.09 53.05±9.27 -0.660 0.511 57.76±10.83 52.69±8.65 2.119 0.037* 52.62±8.88 56.26±9.44 -1.713 0.090 58.58±11.39 54.28±10.95 -1.105 0.277
  Commission errors§ 46.58±9.25 46.35±9.27 46.77±9.31 0.230 0.819 41.88±8.30 47.44±9.28 -2.294 0.024* 46.65±9.41 46.48±9.07 0.076 0.939 49.08±11.03 45.76±9.61 -0.939 0.354
  Perseveration§ 50.74±11.21 50.11±10.06 51.22±12.08 0.502 0.616 50.00±10.95 50.83±11.46 -0.273 0.785 49.88±10.69 53.91±12.88 -1.528 0.130 56.33±16.57 50.44±11.80 -1.245 0.222
 Measures of sustained attention
  HRT block change§ 50.08±10.32 49.09±9.90 50.85±10.64 0.871 0.386 52.29±11.40 49.58±10.26 0.978 0.330 49.05±10.25 53.74±10.15 -1.943 0.055 54.25±6.47 48.92±11.08 -1.538 0.133
 Measures of vigilance
  HRT ISI Change 54.22±9.27 55.76±9.54 53.03±8.96 -1.510 0.134 53.71±8.21 54.35±9.61 -0.258 0.797 53.48±9.25 56.22±8.91 -1.267 0.208 54.00±9.09 53.48±11.13 -0.141 0.889
 Verbal memory
  Immediate recall A1 (verbal) 50.23±7.54 49.89±7.07 50.48±7.93 0.399 0.691 51.76±7.29 50.06±7.63 0.849 0.398 50.99±7.51 47.52±7.32 1.967 0.052 46.08±7.28 51.36±8.67 1.819 0.078
  Immediate recall A5 (verbal) 46.65±13.14 46.11±12.16 47.07±13.93 0.371 0.712 46.53±10.45 46.78±13.68 -0.071 0.943 48.30±13.55 40.61±9.95 2.536 0.013* 39.08±9.79 51.60±15.30 2.581 0.014*
  Immediate recall A1–A5 (verbal) 40.57±9.94 39.87±9.28 41.10±10.46 0.630 0.530 42.00±8.43 40.36±10.28 0.505 0.538 41.61±10.20 36.70±8.24 2.122 0.036* 34.33±5.76 43.32±12.14 3.055 0.004*
 Visual memory
  Immediate recall A1 (visual) 56.37±12.69 56.09±13.64 56.58±12.02 0.843 0.843 58.59±10.94 56.06±12.98 0.752 0.454 57.09±12.49 53.70±13.58 1.129 0.262 51.75±13.14 55.60±13.19 0.832 0.411
  Immediate recall A5 (visual) 67.20±8.95 66.96±9.32 67.38±8.74 0.242 0.809 67.94±8.75 67.00±8.92 0.399 0.691 68.24±8.45 63.35±9.98 2.358 0.020* 63.92±9.49 67.28±8.31 1.101 0.278
  Immediate recall A1–A5 (visual) 59.73±9.81 58.89±10.97 60.37±8.85 0.766 0.445 61.71±8.74 59.45±9.94 0.869 0.387 60.34±9.54 57.43±10.79 1.254 0.213 54.92±5.89 60.12±8.52 1.903 0.065
Wisconsin Card Sorting test
 Total trials 53.46±11.05 52.39±9.44 54.29±12.17 0.900 0.370 55.29±10.39 53.36±11.27 0.652 0.516 54.23±11.01 50.64±11.21 1.355 0.178 45.42±11.87 57.58±10.94 3.058 0.004*
 Total errors 52.34±9.05 51.83±7.95 52.75±9.86 0.515 0.608 53.88±7.18 52.18±9.48 0.702 0.484 52.50±8.75 51.64±10.45 0.394 0.694 44.92±10.87 55.88±7.46 3.557 0.001**
 Perseverative responses 57.50±11.25 57.48±10.54 57.53±11.86 0.021 0.983 57.35±9.04 57.94±11.65 -0.232 0.818 58.17±11.08 55.18±12.03 1.103 0.273 49.33±11.41 61.04±10.03 3.154 0.003*
 Perseverative errors 54.67±9.10 54.41±8.10 54.86±9.88 0.251 0.802 56.12±7.88 54.69±9.29 0.590 0.556 55.15±9.02 52.95±9.59 0.998 0.320 47.67±10.44 57.63±7.53 3.282 0.002*
 Non-perseverative errors 54.46±11.30 54.39±10.14 54.51±12.22 0.052 0.958 55.41±11.59 54.35±11.45 0.347 0.729 54.99±11.10 51.77±11.72 1.192 0.236 50.17±13.53 56.00±10.03 1.462 0.153
Stroop test
 Word 52.06±11.96 52.76±11.99 51.52±12.01 -0.529 0.598 54.88±10.69 51.81±12.00 0.979 0.330 52.60±11.52 50.87±13.37 0.613 0.541 47.17±12.88 50.88±11.30 0.895 0.377
 Color only 46.05±11.70 45.98±11.21 46.10±12.15 0.053 0.958 52.53±13.53 45.07±11.05 2.449 0.017* 46.71±12.06 43.83±10.51 1.040 0.301 40.58±9.11 49.04±12.68 2.063 0.047*
 Color word 47.90±13.24 49.80±11.96 46.43±14.08 -1.303 0.195 52.35±12.61 47.01±13.26 1.530 0.129 48.49±13.44 45.91±12.91 0.819 0.415 39.50±10.21 46.36±12.88 1.614 0.116
 Word of color word 48.65±11.38 48.87±11.63 48.48±11.28 -0.172 0.863 53.00±9.84 47.90±11.52 1.707 0.091 49.55±11.13 46.09±11.93 1.298 0.197 43.00±11.39 48.32±9.95 1.454 0.155
 Color of color word 46.25±13.48 45.48±12.18 46.83±14.48 0.511 0.610 48.53±13.07 46.08±13.74 0.676 0.500 46.62±13.20 44.48±14.76 0.671 0.504 39.33±11.90 47.64±14.61 1.712 0.096
Self-report measures
 K-AADHDS (inattention) 20.58±6.10 21.65±5.36 19.75±6.53 -1.604 0.112 16.18±6.33 21.37±5.75 -3.347 0.001** 20.59±6.09 20.26±6.23 0.225 0.823 21.83±6.13 18.36±7.01 -1.497 0.151
 K-AADHDS (impulsivity/hyperactivity) 16.74±5.89 17.02±4.96 16.52±6.55 -0.452 0.652 13.06±5.24 17.47±5.85 -2.883 0.005* 16.70±5.82 16.70±6.35 0.000 >0.999 16.50±4.50 15.56±6.10 -0.474 0.639
 K-AADHDS (total) 37.31±10.88 38.67±9.17 36.27±12.01 -1.171 0.244 29.24±11.14 38.84±10.33 -3.459 0.001** 37.28±10.63 36.96±12.01 0.126 0.900 38.33±10.14 33.92±12.27 -1.080 0.288
 CES-D (total) 27.36±11.46 24.33±11.35 29.53±11.13 2.322 0.022* 12.12±2.71 30.37±10.00 -14.416 <0.001** 27.78±11.72 25.18±10.29 0.942 0.348 27.73±15.55 26.84±13.73 -0.172 0.865

Values are presented as mean±standard deviation. Statistics was analyzed using Student’s t-test.

*

statistically significant (p<0.05);

**

statistically significant after Bonferroni correction;

poor performance compared to the normal range;

good performance compared to the normal range;

§

lower scores indicate better performance.

ADHD, attention-deficit/hyperactivity disorder; TMT, Trail Making Test; CPT, Continuous Performance Test; K-AADHDS, Korean Adult ADHD Scale; HRT, hit reaction time; HRT ISI, HRT interstimulus interval; CES-D, Center for Epidemiologic Studies Depression Scale; IQ, intelligence quotient

Table 4.

Correlations between self-reported symptoms and neurocognitive parameters (N=106)

Variables K-AADHDS
CES-D
Inattention Impulsivity/hyperactivity Total score
Attention span test
 Forward (auditory) 0.032 0.026 0.032 -0.151
 Backward (auditory) -0.161 -0.098 -0.143 -0.150
 Forward (visual) -0.168 -0.131 -0.165 -0.208*
 Backward (visual) -0.099 -0.008 -0.060 -0.080
Visual TMT
 TMT-A (selective/focused) 0.016 -0.025 -0.005 0.066
 TMT-B (divided) -0.019 -0.020 -0.022 0.026
Conners’ CPT-3
 Measures of inattentiveness
  Detectability 0.355** 0.262** 0.340** 0.241*
  Omission errors 0.296** 0.253** 0.303** 0.058
  Variability 0.253** 0.280** 0.293** 0.130
 Measures of impulsivity
  HRT -0.095 -0.017 -0.062 -0.079
  Commission errors 0.324** 0.131 0.252** 0.295**
  Perseveration 0.238* 0.203* 0.243* 0.123
 Measures of sustained attention
  HRT block change -0.104 -0.179 -0.155 -0.144
 Measures of vigilance
  HRT ISI change 0.276** 0.268** 0.299** -0.005
 Verbal memory
  Immediate recall A1 (verbal) -0.092 -0.054 -0.081 -0.136
  Immediate recall A5 (verbal) -0.069 -0.014 -0.046 -0.022
  Immediate recall A1–A5 (verbal) -0.071 -0.004 -0.042 -0.136
 Visual memory
  Immediate recall A1 (visual) -0.151 -0.158 -0.170 -0.040
  Immediate recall A5 (visual) -0.117 -0.155 -0.150 0.042
  Immediate recall A1–A5 (visual) -0.159 -0.099 -0.143 -0.051
Wisconsin Card Sorting Test
 Total trials -0.129 -0.035 -0.091 -0.127
 Total errors -0.152 -0.058 -0.116 -0.131
 Perseverative responses -0.032 -0.017 -0.027 -0.044
 Perseverative errors -0.042 -0.026 -0.038 -0.026
 Non-perseverative errors -0.009 0.004 -0.003 -0.054
Stroop test
 Word -0.250** -0.265** -0.283** -0.246*
 Color only -0.241* -0.273** -0.283** -0.244*
 Color word -0.171 -0.181 -0.194* -0.349**
 Word of color word -0.203* -0.269** -0.259** -0.336**
 Color of color word -0.163 -0.222* -0.211 -0.117
Self-report measures
 K-AADHDS (inattention) 1 0.649** 0.911** 0.346**
 K-AADHDS (impulsivity/hyperactivity) 0.649** 1 0.905** 0.321**
 K-AADHDS (total) 0.911** 0.905** 1 0.367**
 CES-D (total) 0.346** 0.321** 0.367** 1
FSIQ (N=37)
 Total -0.328* -0.142 -0.260 -0.265
 VCI -0.217 0.080 -0.085 -0.094
 PRI -0.376* -0.056 -0.242 -0.170
 WMI -0.426* -0.137 -0.309 -0.210
 PSI -0.265 -0.189 -0.243 -0.197

Statistics was analyzed using Pearson correlation.

*

statistically significant (p<0.05);

**

statistically significant (p<0.01);

lower scores indicate better performance.

TMT, Trail Making Test; CPT, Continuous Performance Test; HRT, hit reaction time; HRT ISI, HRT interstimulus interval; K-AADHDS, Korean Adult ADHD Scale; CES-D, Center for Epidemiologic Studies Depression Scale; FSIQ, Full Scale Intelligence Quotient; VCI, Verbal Comprehension Index; PRI, Perceptual Reasoning Index; WMI, Working-Memory Index; PSI, Processing Speed Index; ADHD, attention-deficit/hyperactivity disorder

Table 5.

Neurocognitive parameters significantly associated with the K-AADHDS score according to stepwise multivariate linear regression

Adjusted R2 B SE β t p
K-AADHDS (inattention)
 (Constant) 0.362 -0.214 5.049 -0.042 0.966
 CES-D total 0.241 0.065 0.500 3.698 0.001
 HRT ISI change 0.241 0.087 0.373 2.758 0.009
K-AADHDS (impulsivity-hyperactivity)
 (Constant) 0.165 2.517 3.429 0.734 0.465
 CES-D total 0.168 0.047 0.323 3.564 0.001
 HRT ISI change 0.178 0.058 0.279 3.080 0.003
K-AADHDS (total score)
 (Constant) 0.430 -2.249 8.555 -0.263 0.794
 CES-D total 0.384 0.112 0.457 3.426 0.002
 HRT ISI change 0.506 0.148 0.457 3.424 0.002
CES-D (total score)
 (Constant) 0.278 4.840 6.158 0.786 0.438
 K-AADHDS (inattention) 1.126 0.030 0.547 3.755 0.001

Statistics was analyzed using stepwise multiple linear regression analysis. HRT ISI, hit reaction time interstimulus interval; K-AADHDS, Korean Adult ADHD Scale; CES-D, Center for Epidemiologic Studies Depression Scale; SE, standard error; ADHD, attention-deficit/hyperactivity disorder